Nantkwest (NK) and Oncobiologics (ONS) Head-To-Head Analysis

Nantkwest (NASDAQ:NK) and Oncobiologics (NASDAQ:ONS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk.

Institutional and Insider Ownership

Get Nantkwest alerts:

12.5% of Nantkwest shares are owned by institutional investors. Comparatively, 7.2% of Oncobiologics shares are owned by institutional investors. 72.3% of Nantkwest shares are owned by company insiders. Comparatively, 11.5% of Oncobiologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Nantkwest and Oncobiologics’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nantkwest	$50,000.00	1,885.58	-$96.42 million	($1.20)	-0.99
Oncobiologics	$3.81 million	0.00	-$38.84 million	N/A	N/A

Oncobiologics has higher revenue and earnings than Nantkwest.

Volatility & Risk

Nantkwest has a beta of 2.7, meaning that its share price is 170% more volatile than the S&P 500. Comparatively, Oncobiologics has a beta of -0.27, meaning that its share price is 127% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Nantkwest and Oncobiologics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nantkwest	0	2	0	0	2.00
Oncobiologics	0	0	0	0	N/A

Nantkwest presently has a consensus price target of $2.75, indicating a potential upside of 131.09%.

Profitability

This table compares Nantkwest and Oncobiologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nantkwest	-198,790.38%	-54.20%	-46.28%
Oncobiologics	-464.47%	N/A	-93.28%

About Nantkwest

NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer product candidates primarily for the treatment of various cancers; and target activated natural killer product candidates to treat hematological malignancies and solid tumors. NantKwest, Inc. has a co-development agreement with Altor Bio Science Corporation to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.

About Oncobiologics

Oncobiologics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics in immunology and oncology disease areas. Its advanced product candidate is ONS-3010, an adalimumab biosimilar that is in a Phase 1 clinical trial, which targets the tumor necrosis factor alpha. The company also develops ONS-1045, a bevacizumab biosimilar, which is in a Phase 1 clinical trial that interferes with tumor growth by binding to vascular endothelial growth factor, a protein that stimulates the formation of new blood vessels. Its advanced preclinical product candidate is ONS-1050, a trastuzumab biosimilar, interferes with the human epidermal growth factor receptor 2, a protein that stimulates cell proliferation. Oncobiologics, Inc. has collaboration and license agreements with Selexis SA; IPCA Laboratories Limited; Laboratories Liomont, S.A. de C.V.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.